Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulato...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ustekinumab in Infliximab-refractory Pediatric UC Ustekinumab in Infliximab-refractory Pediatric UC
This study evaluated the efficacy of ustekinumab following failure of prior biologics in pediatric ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Avsola (Infliximab-axxq for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Avsola (infliximab-axxq)
Title: Avsola (infliximab-axxq)Category: MedicationsCreated: 5/28/2021 12:00:00 AMLast Editorial Review: 5/28/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 28, 2021 Category: Drugs & Pharmacology Source Type: news

Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
TUESDAY, May 18, 2021 -- Individuals with inflammatory bowel disease who are treated with infliximab rather than vedolizumab have reduced immunogenicity to a single dose of BNT162b2 and ChAdOx1 nCoV-19 severe acute respiratory syndrome coronavirus 2... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2021 Category: Pharmaceuticals Source Type: news

Double Switching From Infliximab to Biosimilars in IBD Double Switching From Infliximab to Biosimilars in IBD
Does double switching from infliximab to the biosimilars CT-P13 and then to SB2 impair the effectiveness, immunogenicity or safety of anti-TNF therapy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Researchers Urge Second COVID Vaccine Dose for Infliximab Users Researchers Urge Second COVID Vaccine Dose for Infliximab Users
Patients being treated with infliximab had weakened immune responses to the first dose of the Pfizer and AstraZeneca COVID vaccines compared with patients on vedolizumab, according to a new UK study.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 7, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Infliximab Weakens COVID Antibody Response for Patients With IBD Infliximab Weakens COVID Antibody Response for Patients With IBD
Although anti-tumor necrosis factor (anti-TNF) drugs are routinely used for patients with IBD, the impact of their immune-suppressing properties on protective immunity to COVID-19 is unknown.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 25, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Infliximab May Impede Serologic Response to SARS-CoV-2
TUESDAY, March 23, 2021 -- For patients with inflammatory bowel disease (IBD), infliximab is associated with attenuated serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2021 Category: Pharmaceuticals Source Type: news

Common inflammatory bowel disease treatment linked to reduced COVID-19 antibody response
(University of Exeter) The findings arose from the CLARITY study, which recruited 6,935 patients with Crohn's disease and ulcerative colitis from 92 UK hospitals between September and December 2020. It found that fewer than half of people with IBD who were treated with infliximab had detectable antibodies after SARS-CoV-2 infection, the coronavirus that causes COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news

Egis Pharmaceuticals PLC Announces Registration of the First...
Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020.(PRWeb March 16, 2021)Read the full story at https://www.prweb.com/releases/egis_pharmaceuticals_plc_announces_registration_of_the_first_blood_based_ce_ivd_precision_medicine_tool_for_therapy_selection_in_rheumatoid_arthritis/prweb17793650.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 16, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

An interspecies translation model implicates integrin signaling in infliximab-resistant inflammatory bowel disease
Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with pa...
Source: Signal Transduction Knowledge Environment - August 3, 2020 Category: Science Authors: Brubaker, D. K., Kumar, M. P., Chiswick, E. L., Gregg, C., Starchenko, A., Vega, P. N., Southard-Smith, A. N., Simmons, A. J., Scoville, E. A., Coburn, L. A., Wilson, K. T., Lau, K. S., Lauffenburger, D. A. Tags: STKE Research Articles Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Vedolizumab and Infliximab in UC After Failure of Anti-TNF Vedolizumab and Infliximab in UC After Failure of Anti-TNF
In this study, in patients with ulcerative colitis refractory to an anti-TNF agent, vedolizumab was more effective than infliximab in achieving clinical remission.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Biosimilar ABP 710 vs Infliximab Reference Product in RA Biosimilar ABP 710 vs Infliximab Reference Product in RA
Might this new biosimilar be a viable treatment option for patients with rheumatoid arthritis? How does it compare with infliximab reference product?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Determining Therapeutic Range of Anti-TNF Therapies in IBD Determining Therapeutic Range of Anti-TNF Therapies in IBD
This review describes the principles and process followed to define the target therapeutic ranges for infliximab and adalimumab in the treatment of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New UC Guidelines Preferentially Rank Biologics New UC Guidelines Preferentially Rank Biologics
New guidance for moderate to severe UC prioritizes early use of biologics after 5-ASA failure and preferentially ranks infliximab and golimumab as first-line options in biologic-na ï ve patients.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 4, 2020 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Ixifi (Infliximab-qbtx for Injection, for Intravenous Use ) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 3, 2020 Category: Drugs & Pharmacology Source Type: news

Havertown Doctor Pleads Guilty to Unlawfully Importing Foreign, Injectable Drugs and Unlawfully Distributing Oxycodone
Thomas Whalen, Havertown PA, Guilty plea, importation, heath care fraud, oxycodone, D.O., controlled substance, Whalen Rheumatology Group, Exton PA, Wilmington DE, Unapproved, Injection, Infusion, Remicade Synvisc, Synvisc-One, Orencia, Prolia/Xgeva, Boniva (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - December 19, 2019 Category: Medical Law Authors: DOJ Source Type: news

Doctors warn Crohn's, arthritis patients will pay a price as Alberta pulls drug funding
Doctors say 2,000 patients in Alberta will pay a price with the government's plan to stop funding Remicade, a drug used to treat people with Crohn's and colitis. (Source: CBC | Health)
Source: CBC | Health - December 17, 2019 Category: Consumer Health News Tags: News/Canada/Calgary Source Type: news

Avsola (Infliximab-axxq for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 11, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves Amgen's Biosimilar to J & J's Rheumatoid Arthritis Drug FDA Approves Amgen's Biosimilar to J & J's Rheumatoid Arthritis Drug
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson& Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - December 10, 2019 Category: Orthopaedics Tags: Pharmacist News Source Type: news

FDA approves Amgen's biosimilar to J & J's rheumatoid arthritis drug
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson& Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
THOUSAND OAKS, Calif., Dec. 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Avsola (infliximab-axxq) for all approved indications of the reference product, Remicade®... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 6, 2019 Category: Drugs & Pharmacology Source Type: news

Reimbursing infliximab for Crohn's disease cost effective in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2019 Category: Drugs & Pharmacology Source Type: news

J & J blockbuster loses ground to biosimilars despite Quebec court ruling
Johnson& Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

J & J's Remicade losing ground in Quebec health plan despite court victory
Johnson& Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Infliximab Induction in Refractory Acute Severe Colitis Infliximab Induction in Refractory Acute Severe Colitis
Does an accelerated induction rescue therapy regimen of infliximab improve response rates compared to standard-dose therapy in patients with steroid-refractory acute severe colitis?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis Effectiveness of Infliximab vs. Biosimilar CT-P13 in Colitis
The infliximab biosimilar CT-P13 has been approved for the treatment of ulcerative colitis. Are they clinically equivalent in safety and efficacy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

infliximab (Remicade)
Title: infliximab (Remicade)Category: MedicationsCreated: 12/13/1999 12:00:00 AMLast Editorial Review: 9/20/2019 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 20, 2019 Category: Drugs & Pharmacology Source Type: news

Effects of Infliximab Withdrawal and Reintroduction in Ankylosing Spondylitis Patients in Persistent Clinical Remission
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 15, 2019 Category: Orthopaedics Tags: CME Article Source Type: news

FTC probing J & amp;J over arthritis drug Remicade
The organization issued a civil investigative demand to the drugmaker to see if its biosimilar defense strategy violates federal antitrust laws. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 30, 2019 Category: Pharmaceuticals Source Type: news

J & J says FTC probing efforts to protect arthritis drug Remicade
The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Withdrawal of Infliximab Therapy in Ankylosing Spondylitis Withdrawal of Infliximab Therapy in Ankylosing Spondylitis
Should infliximab withdrawal be considered for ankylosing spondylitis patients who have achieved clinical remission? What are the effects of reintroduction?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Biologics in IBD: More Thoughtful Use Could Improve Outcomes Biologics in IBD: More Thoughtful Use Could Improve Outcomes
The marketplace introduction of infliximab for the treatment of IBD did not reduce hospitalization or surgery rates in a large population of patients with Crohn disease and ulcerative colitis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 20, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Infliximab Introduction Has Not Cut IBD-Related Hospitalizations
FRIDAY, June 14, 2019 -- Marketplace introduction of infliximab has not resulted in reductions in the population rates of inflammatory bowel disease (IBD)-related hospitalizations or intestinal resections or colectomies, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 14, 2019 Category: Pharmaceuticals Source Type: news

Targeting Inflammation May Help Bipolar Depression Subtype Targeting Inflammation May Help Bipolar Depression Subtype
The anti-inflammatory agent infliximab may improve depressive symptoms in patients with bipolar depression and a history of childhood trauma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 20, 2019 Category: Consumer Health News Tags: Psychiatry News Source Type: news

IBD: Optimized Infliximab Monotherapy vs Combination Therapy IBD: Optimized Infliximab Monotherapy vs Combination Therapy
This study compared the clinical efficacy and cost of two different IBD treatment strategies for the introduction of infliximab: 6-12 months in combination with azathioprine versus optimized monotherapy.Alimentary Pharmacology & Therapeutics (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 29, 2019 Category: Allergy & Immunology Tags: Gastroenterology Journal Article Source Type: news

Infliximab Biosimilar CT-P13 Noninferior in Active Crohn's Disease Infliximab Biosimilar CT-P13 Noninferior in Active Crohn's Disease
The infliximab biosimilar CT-P13 is noninferior to infliximab for treating patients with active Crohn's disease, according to a randomized controlled trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 11, 2019 Category: Orthopaedics Tags: Gastroenterology News Source Type: news

Infliximab and Risk of Serious Infection in Psoriasis Infliximab and Risk of Serious Infection in Psoriasis
Does infliximab increase the risk of serious infection as compared to nonbiologic systemic therapies in patients with psoriasis?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Predicting Relapse Following Infliximab De-escalation in IBD Predicting Relapse Following Infliximab De-escalation in IBD
This study aimed to assess the rate of relapse following infliximab de-escalation in IBD patients in remission. How might infliximab trough level impact relapse?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Laparoscopic Surgery for Crohn's More Cost-Effective Than Infliximab (CME/CE)
(MedPage Today) -- More QALYs gained, 1-year health-related costs less (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - February 10, 2019 Category: Surgery Source Type: news

Laparoscopic Resection in Crohn's More Cost-Effective Than Infliximab
(MedPage Today) -- More QALYs gained and 1-year health costs were $10,000 less in European study (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 5, 2019 Category: Gastroenterology Source Type: news

Switching Between Reference and Biosimilar Infliximab Switching Between Reference and Biosimilar Infliximab
Is switching between infliximab and its biosimilar safe and efficacious in patients with inflammatory disorders?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news